Quoin Pharmaceuticals grants CFO options on 10,330 ADSs at $19.36

Quoin Pharmaceuticals, Ltd. reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor, in a Form 4 filing.

Rhea-AI Filing Summary

Quoin Pharmaceuticals, Ltd. reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor, in a Form 4 filing. The grant covers an option to buy 10,330 American Depositary Shares (ADSs) at an exercise price of $19.36 per ADS, with each ADS representing thirty-five ordinary shares of Quoin. The option was approved by the company’s Compensation Committee on December 1, 2025 and expires on December 1, 2035.

The option vests over four years, with 20% of the ADSs vesting on each of December 1, 2026, 2027 and 2028, and the remaining 40% vesting on December 1, 2029. This filing reflects an equity-based component of the CFO’s compensation, designed to align her interests with long-term shareholder value.

Insider Trade Summary

Grant/Award: 10,330 shares

Grant/Award 1 txn

Insider Lawlor Sally Bridget

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	10,330	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 10,330 contracts (Direct)

Footnotes (3)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.
3. F3. The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Quoin Pharmaceuticals (QNRX) disclose in this Form 4?

Quoin Pharmaceuticals disclosed that its Chief Financial Officer, Sally Bridget Lawlor, received a stock option grant covering 10,330 ADSs at an exercise price of $19.36 per ADS.

Who is the reporting person in the Quoin Pharmaceuticals (QNRX) Form 4?

The reporting person is Sally Bridget Lawlor, who serves as Chief Financial Officer of Quoin Pharmaceuticals, Ltd.

What are the main terms of the QNRX CFO stock option grant?

The CFO received an option to buy 10,330 ADSs at $19.36 per ADS, approved on December 1, 2025, with an expiration date of December 1, 2035.

How does the Quoin Pharmaceuticals (QNRX) stock option vest for the CFO?

The option vests in four installments: 20% on each of December 1, 2026, December 1, 2027, and December 1, 2028, and the remaining 40% on December 1, 2029.

What does each ADS represent in the QNRX CFO option grant?

Each American Depositary Share (ADS) in the grant represents thirty-five ordinary shares of Quoin Pharmaceuticals, Ltd.

Is this Quoin Pharmaceuticals (QNRX) Form 4 about derivative or non-derivative securities?

This Form 4 primarily reports a derivative security: a stock option (right to buy) over 10,330 ADSs of Quoin Pharmaceuticals, Ltd.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/03/2025 - 05:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawlor Sally Bridget

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$19.36(1)	12/01/2025(2)		A		10,330(1)		(3)	12/01/2035	ADS(1)	10,330(1)	$0	10,330(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.

3. The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.

	/s/ Sally Bridget Lawlor	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.